Estrogen Patch Shortage May Persist for a Year or More
Surging demand for menopause treatments has created a nationwide estrogen patch shortage that manufacturers may need over a year to resolve.
A growing shortage of estrogen patches is straining access to one of the most commonly prescribed menopause treatments in the United States, and experts warn that relief may not arrive for at least a year. The supply crunch reflects a broader surge in demand for hormone therapy options as menopause care has gained renewed clinical and cultural attention in recent years.
The gap between supply and demand puts pressure on patients who depend on transdermal estrogen delivery — patches applied to the skin — as a preferred method for managing symptoms such as hot flashes, sleep disruption, and mood changes associated with menopause. Unlike oral hormone pills, patches offer a steady hormone release and are often recommended for women with certain health considerations, making them difficult to simply swap out for an alternative.
Read more GLP-1 Weight Loss Pills: Why Employers May Not Cover Them →
Manufacturers appear to be struggling to scale production fast enough to meet the accelerating demand, a dynamic that industry observers note can take considerable time to remedy given the regulatory complexity of pharmaceutical manufacturing. The timeline of at least one year suggests the shortage is structural rather than a temporary logistics hiccup — meaning patients and physicians will need to navigate workarounds for the foreseeable future.
The situation highlights a recurring vulnerability in specialty pharmaceutical supply chains: when demand for a long-established drug category rises sharply, production capacity rarely scales in parallel. Clinicians facing shortages may consider compounded formulations or alternative estrogen delivery methods, though these substitutions carry their own clinical trade-offs and require careful patient-provider discussion.
Continue reading at US Top News and Analysis.
